Alumis Inc. cash flow statement
In fiscal 2025, Alumis Inc.'s operations generated −$370m of cash; it spent $653,000 on capital projects, leaving free cash flow of −$370m. It returned $17,000 through buybacks.
Cash flow statement
| Quarter | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | −80 | −106 | −111 | −72 | −87 | −82 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 7 | 19 | 10 | 8 | 12 | 14 |
| Capital spending | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −80 | −107 | −111 | −72 | −87 | −82 |
| Free cash flow after stock pay | −87 | −126 | −121 | −80 | −100 | −96 |
| Shares issued | — | — | — | — | 324 | 0 |
Compare with peers
- Evaxion A/s cash flow
- Roivant Sciences Ltd. cash flow
- Adagene Inc. cash flow
- Tscan Therapeutics, Inc. cash flow
- Coya Therapeutics, Inc. cash flow
Head to head: ALMS vs EVAXALMS vs ROIVADAG vs ALMS
More: Biotechnology stocks compared, Health Care sector, rankings of US companies